Disitamab Vedotin, Tislelizumab, and S-1 Tested in HER2-Positive Gastric Cancer
Phase II trial tested first-line disitamab vedotin, tislelizumab, and S-1 in HER2-overexpressing advanced gastric or GEJ adenocarcinoma.
This section contains the website’s posts.